Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 11/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7383773 | 1.00 | CCR2 (0.50) | CCR2RAB9AALDH1A1NPC1HPGDS | |
| SCHEMBL14778920 | 1.00 | CCR2 (0.50) | CCR2RAB9AALDH1A1NPC1HPGDS | |
| SCHEMBL7238979 | 0.88 | CCR2 (0.60) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL320179 | 0.88 | CCR2 (0.60) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL20581684 | 0.88 | CCR2 (0.60) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL3241217 | 0.86 | CCR2 (0.68) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL319610 | 0.86 | CCR2 (0.68) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL3487757 | 0.86 | CCR2 (0.68) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL7238858 | 0.85 | CCR2 (0.71) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL23571243 | 0.82 | CCR2 (0.49) | CCR2RAB9AALDH1A1HPGDSKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024121779-A1 | PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS | PFIZER INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023244059-A1 | METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-4259634-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-2686321-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Bristol-Myers Squibb Company (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| WO-2013092756-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2013-06-27 | — | — | WO | disclosed |
| EP-2606893-A1 | Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012125893-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| CN-101490024-A | Substituted phenylacetic acids as DP-2 antagonists | ICOS CORP (US) | 2009-07-22 | — | — | CN | disclosed |
| EP-2044044-A2 | SUBSTITUTED PHENYL ACETIC ACIDS AS DP-2 ANTAGONISTS | ICOS CORPORATION (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-2029581-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007143745-A2 | SUBSTITUTED PHENYL ACETIC ACIDS AS DP-2 ANTAGONISTS | ICOS CORPORATION (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007126871-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | CCR2 20/4885RAB9A 3279/4885ALDH1A1 3765/4885 |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | CCR2 2411/4885RAB9A 3174/4885ALDH1A1 272/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | CCR2 1322/4885RAB9A 2466/4885ALDH1A1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.